Ranibizumab Effective for Pigment Epithelial Detachment Ranibizumab Effective for Pigment Epithelial Detachment

Low-dose ranibizumab is effective in treating pigment epithelial detachment in patients with neovascular age-related macular degeneration, a post hoc analysis of the HARBOR study suggests.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Related Links:

Publication date: Available online 10 October 2019Source: Life SciencesAuthor(s): Pallavi Gupta, Khushwant S. YadavAbstractTreatment of majority of eye diseases involve the use of eye drops or eye ointments, which have major drawbacks of needing frequent administration, lower bioavailability and inability to cross the various eye barriers. This necessitates the use of novel delivery systems. Microneedles (MNs) as an alternate novel delivery system facilitate drug delivery to various ocular diseases with promising approaches in healthcare. Advances in pharmaceutical technology have made MNs provide localized, effective, les...
Source: Life Sciences - Category: Biology Source Type: research
NIH Director's Wednesday Afternoon Lecture Series Age-related macular degeneration (AMD) is the leading cause of blindness in the United States and in the developed world. Two NIH-supported randomized clinical trials with 10 years of follow-up in nearly 10,000 participants demonstrated that nutritional supplements with antioxidant vitamins and minerals reduces the risk of progression to late AMD. Dietary data suggest the importance of the Mediterranean diet in reducing the risk of AMD, particularly fish consumption. The analyses of the genetic interaction with nutrition challenges the idea that you can eat away your geneti...
Source: Videocast - All Events - Category: General Medicine Tags: Upcoming Events Source Type: video
This case report describes an elderly man with neovascular age-related macular degeneration with a new spot on his eye.
Source: JAMA Ophthalmology - Category: Opthalmology Source Type: research
To report and compare 10-year treatment outcomes of vascular endothelial growth factor (VEGF) inhibitors for neovascular age-related macular degeneration (nAMD) from Australia and New Zealand (ANZ) and Switzerland.
Source: American Journal of Ophthalmology - Category: Opthalmology Authors: Tags: Original Articles Source Type: research
To assess the prevalence of age-related macular degeneration (AMD) in a Russian population.
Source: American Journal of Ophthalmology - Category: Opthalmology Authors: Tags: Original Articles Source Type: research
Authors: Elbaz-Hayoun S, Rinsky B, Hagbi-Levi S, Grunin M, Tammy HayaYedid, Chowers I Abstract Purpose: Oxidative stress and macrophages have been implicated in the pathogenesis of atrophic and neovascular age-related macular degeneration (aAMD and nvAMD). It is unclear whether oxidative injury mediates macrophage involvement in AMD. We aimed to investigate the effect of antioxidant treatments on human monocyte-derived macrophages (hMDMs) from patients with AMD in models for the disease. Methods: Four antioxidant treatments were evaluated (G1: lutein + zeaxanthin, G2: lutein + zeaxanthin and zinc, G3: lutein + ...
Source: Molecular Vision - Category: Molecular Biology Tags: Mol Vis Source Type: research
Beovu injections treat wet age-related macular degeneration that affects 20 million people worldwide, according to the company
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news
The US Food and Drug Administration approved brolucizumab (Beovu, Novartis) injection for wet age-related macular degeneration (AMD).FDA Approvals
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Ophthalmology News Alert Source Type: news
EAST HANOVER, N.J., Oct. 8, 2019 /PRNewswire/ -- Novartis today announced that the U.S. Food and Drug Administration (FDA) approved Beovu (brolucizumab-dbll) injection, also known as RTH258, for the treatment of wet age-related macular degeneration...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
Journal of Human Hypertension, Published online: 08 October 2019; doi:10.1038/s41371-019-0269-9Hypertension, antihypertensive medications use and risk of age-related macular degeneration in California Teachers Cohort
Source: Journal of Human Hypertension - Category: Cardiology Authors: Source Type: research
More News: Age-Related Macular Degeneration (AMD) | Health | Lucentis | Opthalmology | Ranibizumab Injection | Study